Alaunos Therapeutics, Inc. (TCRT)

Market Cap	3.14M
Revenue (ttm)	7,000
Net Income (ttm)	-11.78M
Shares Out	1.60M
EPS (ttm)	-7.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,600
Open	2.040
Previous Close	2.020
Day's Range	1.950 - 2.040
52-Week Range	1.630 - 33.000
Beta	-0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About TCRT

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleepi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: TCRT
• Website: https://www.alaunos.com

Financial Performance

In 2023, Alaunos Therapeutics's revenue was $5,000, a decrease of -99.83% compared to the previous year's $2.92 million. Losses were -$35.14 million, -6.86% less than in 2022.